Immunotherapy in Ovarian Cancer: Where Are We Now, and Where Are We Going? 

  H&O  What types of immunotherapy have been investigated for use in women with ovarian cancer? AJ  The 3 broad areas of immunotherapy that have been […]

Optimal Treatment for Platinum-Sensitive Recurrent Ovarian Cancer

  H&O  How common is ovarian cancer? BJM  The American Cancer Society estimates that ovarian cancer will be diagnosed in 22,440 women and that 14,080 women […]

The Status of Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer, Part 2: Extending the Scope Beyond Olaparib and BRCA1/2 Mutations

  Abstract: Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have shown clinical activity in epithelial ovarian cancer, leading both the US Food and Drug Administration (FDA) and the […]

The Status of Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer, Part 1: Olaparib

  Abstract: Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have shown promising clinical activity in epithelial ovarian cancer. Following the observation in vitro that PARP inhibition is synthetically […]

Neoadjuvant Chemotherapy for Advanced Epithelial Ovarian Cancer

Abstract: The historical standard treatment paradigm for advanced epithelial ovarian cancer is surgical staging followed by adjuvant platinum- and taxane-based chemotherapy. It is well established that […]